Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy.
about
Hydroxychloroquine-related retinal toxicityAutophagy and heterophagy dysregulation leads to retinal pigment epithelium dysfunction and development of age-related macular degenerationThymoquinone inhibits autophagy and induces cathepsin-mediated, caspase-independent cell death in glioblastoma cellsThe impact of different algorithms for ideal body weight on screening for hydroxychloroquine retinopathy in women.Relative sensitivity and specificity of 10-2 visual fields, multifocal electroretinography, and spectral domain optical coherence tomography in detecting hydroxychloroquine and chloroquine retinopathy.Regular examinations for toxic maculopathy in long-term chloroquine or hydroxychloroquine users.Chloroquine cardiomyopathy - a review of the literature.A comparison of structural and functional changes in patients screened for hydroxychloroquine retinopathy.Humphrey visual field findings in hydroxychloroquine toxicityA possible early sign of hydroxychloroquine macular toxicity.Spectral-Domain Optical Coherence Tomography of Preclinical Chloroquine Maculopathy in Egyptian Rheumatoid Arthritis Patients.Ocular manifestations of systemic lupus erythematosus: a review of the literatureDiscovery of New Classes of Compounds that Reactivate Acetylcholinesterase Inhibited by OrganophosphatesChloroquine retinopathy: pattern of presentation in Ibadan, Sub-Sahara AfricaSpectral domain optical coherence tomography for early detection of retinal alterations in patients using hydroxychloroquineEffect of Hydroxychloroquine on the Retinal Layers: A Quantitative Evaluation with Spectral-Domain Optical Coherence Tomography.Frequency and Clinical Characteristics of Hydroxychloroquine Retinopathy in Korean Patients with Rheumatologic Diseases.Hydroxychloroquine and smoking in patients with cutaneous lupus erythematosus.Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects.Ocular complications associated with systemic medications used in allergy/immunology practice.Hydrochloroquine retinopathy: characteristic presentation with review of screening.Approaches for detecting lysosomal alkalinization and impaired degradation in fresh and cultured RPE cells: evidence for a role in retinal degenerations.Study protocol of a phase IB/II clinical trial of metformin and chloroquine in patients with IDH1-mutated or IDH2-mutated solid tumoursNew Perspectives in Rheumatology: Avoiding Antimalarial Toxicity.SAR study to find optimal cholinesterase reactivator against organophosphorous nerve agents and pesticides.Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients.Screening for chloroquine maculopathy in populations with uncertain reliability in outcomes of automatic visual field testingChloroquine and hydroxychloroquine binding to melanin: Some possible consequences for pathologiesDecreased Perifoveal Sensitivity Detected by Microperimetry in Patients Using Hydroxychloroquine and without Visual Field and Fundoscopic Anomalies.ERG and other discriminators between advanced hydroxychloroquine retinopathy and retinitis pigmentosa.Cystoid macular oedema and epiretinal membrane formation during progression of chloroquine retinopathy after drug cessation.Chloroquine and hydroxychloroquine retinopathy-related risk factors in a Turkish cohort.[Ophthalmologic screening history and vision-targeted health status of patients suffering from chloroquine maculopathy].Response to hydroxychloroquine in Japanese patients with systemic lupus erythematosus using the cutaneous lupus erythematosus disease area and severity index (CLASI).Multifocal electroretinograms.Autoimmune retinopathy associated with systemic lupus erythematosus: A diagnostic dilemma.Retinal Toxicity Induced by a Novel β-secretase Inhibitor in the Sprague-Dawley Rat.Macular ganglion cell-inner plexiform layer thickness for detection of early retinal toxicity of hydroxychloroquine.Antimalarial-induced cardiomyopathy: a systematic review of the literature.Hydroxychloroquine-induced retinopathy in a 57-year-old woman.
P2860
Q26782822-A229B0DE-1834-4D54-BF1A-C190E3B1B8D4Q27008407-32B344A2-CAA1-4CEF-BF1C-DE6D7986B33DQ28536969-7F9386D9-8632-4300-8517-A66C3D81F120Q33976159-608FF785-BC6D-4575-BDEA-9D792519AE59Q34005507-22973BBF-1407-455F-B085-C4416B18AE66Q34315879-A3CF51C6-9E58-4B35-804B-C5D8A638C754Q34342236-83EFF80A-8828-42C3-A59A-EC706BEC0AD7Q35001994-127774D0-8090-425B-9A4A-445BAD29DD39Q35603566-58967ABC-FAD3-482D-958D-9A1FEF6E76CEQ35899646-336503A3-21EC-42B6-B478-5185EDE41BF0Q35957874-2F048D06-BDE7-4027-B06C-5279699C295CQ36091026-09555A0E-E664-45CE-AF17-96D3C826516FQ36331614-9771E6BE-1200-4932-BB7E-FD2B5CC23E38Q36453295-5B88C4F9-43B6-4D24-8729-DEFC3C989473Q37023500-807911B1-E992-4463-95B1-3DBCE90E31A4Q37253124-D9E6CBCF-17B9-4EED-855C-63FA4843D67BQ37622345-C8CA9EE7-046B-46B9-9BAA-ADDA71CAA175Q38009852-9E723170-47B0-447A-944C-4AF0B52B5675Q38029146-71F4F57E-5357-46D0-BD5A-B98B62572026Q38071560-29112919-5EF2-46B0-801E-08CCA5B4D31EQ38091637-3DF31235-CE53-42AF-8377-DC5B0A37EFE7Q38242790-432AA8B1-A7A4-49B0-9F53-A11DEFA43BAAQ38375735-3859F3CE-1B76-4CEC-A16F-A94E48EA24F2Q38816742-298CCB7F-7799-464A-BC7C-D960E9E250E6Q38942948-2FE4F06F-3F6E-499C-89A8-81AFC75E2BC8Q39062828-FF70F512-D444-4285-B807-E6769F5CBDC9Q39396583-78AC05C8-26A2-44A5-8228-ACEB4B011516Q41680951-9E523EA5-0716-4EFA-BF46-2784FC465942Q41872366-E6927141-B0B0-4004-9710-2DE977D1868CQ41912830-030FDDF3-B0AA-4C34-A165-D412EAC79F4DQ41923610-93143551-6A61-46E5-A2E0-8F978FAB9B39Q41926617-4BF4D2D5-3673-423A-B3CA-509815419AA5Q41928391-1352F5B9-248D-47FA-AD5D-6560E898DD7BQ41931972-6339BB15-42B7-4F5B-86CB-C5FF476A3B8EQ41996400-40253B6B-E05F-48D1-8492-7DACBCD5430BQ42375302-BE500B34-F09B-41E2-AFB4-BA0DFFAE5284Q46429003-E2403FE4-DA84-44F8-ACBF-9CBC96B85199Q47770741-BE73B6DF-BCA4-4596-80F0-85D2FF75E151Q49383501-D308D4FD-2788-4EF1-B5A3-7B10FB6BC108Q49864093-98C217EE-EFCF-442C-8270-F390E7A8D909
P2860
Retinal toxicity associated with hydroxychloroquine and chloroquine: risk factors, screening, and progression despite cessation of therapy.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Retinal toxicity associated wi ...... despite cessation of therapy.
@ast
Retinal toxicity associated wi ...... despite cessation of therapy.
@en
Retinal toxicity associated wi ...... despite cessation of therapy.
@nl
type
label
Retinal toxicity associated wi ...... despite cessation of therapy.
@ast
Retinal toxicity associated wi ...... despite cessation of therapy.
@en
Retinal toxicity associated wi ...... despite cessation of therapy.
@nl
prefLabel
Retinal toxicity associated wi ...... despite cessation of therapy.
@ast
Retinal toxicity associated wi ...... despite cessation of therapy.
@en
Retinal toxicity associated wi ...... despite cessation of therapy.
@nl
P2093
P1433
P1476
Retinal toxicity associated wi ...... despite cessation of therapy.
@en
P2093
Michel Michaelides
Niamh B Stover
Peter J Francis
Richard G Weleber
P356
10.1001/ARCHOPHTHALMOL.2010.321
P407
P577
2011-01-01T00:00:00Z